摘要:
A novel process for preparing enantiomerically-pure 3-methyl-5-(1-(C1-C3-alkyl)-2-pyrrolidinyl)isoxazole in high yield, wherein a protected pyrrolidine or 2-oxo-pyrrolidine starting material is reacted with a suitable organic anion and a resulting beta-keto oxime intermediate is cyclized and dehydrated, as well as intermediates useful in the preparation thereof.
摘要:
A novel process for preparing enantiomerically-pure 3-methyl-5-(1-(C1-C3-alkyl)-2-pyrrolidinyl)isoxazole in high yield, wherein a protected pyrrolidine or 2-oxo-pyrrolidine starting material is reacted with a suitable organic anion and a resulting beta-keto oxime intermediate is cyclized and dehydrated, as well as intermediates useful in the preparation thereof.
摘要:
Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.
摘要:
Novel 3-pyridyloxymethyl heterocyclic ether compounds of formula (I) or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula (I) with the variables defined in the specification are also described.
摘要:
Agonistes nicotiniques, sélectifs et puissants, de la formule (I), ou sels pharmaceutiquement acceptables de ceux-ci, utilisés dans le traitement de troubles mentaux, neurologiques et cognitifs caractérisés par une diminution des fonctions cholinergiques.
摘要:
Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R1, R2, A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.
摘要:
Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.
摘要:
Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R1, R2, A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.
摘要:
Selective and potent nicotinic agonists of formula (I), or pharmaceutically-acceptable salts thereof, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.